Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Clinical trial NCT04586088 · UNKNOWN

Trial details

NCT number: NCT04586088
Sponsor: Sun Yat-sen University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Nasopharyngeal Carcinoma Recurrent Nasopharyngeal Carcinoma Metastatic Nasopharyngeal Carcinoma Chemotherapy Effect Immunotherapy Molecular Targeted Therapy

Start date: 2020-05-05
Primary completion: 2022-06-02
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.